9. Psilocybin for Alcohol Use Disorder

9. Psilocybin for Alcohol Use Disorder

Imagine finding a new ally in the battle against alcohol use disorder. In this episode of 'Addiction Medicine Journal Club', Dr. Sonya Del Tredici and Dr. John Keenan take a deep dive into the promising world of psilocybin-assisted psychotherapy. They dissect a groundbreaking study published in JAMA Psychiatry, which shows a significant reduction in heavy drinking days for those treated with psilocybin compared to a placebo. The hosts explore how this psychedelic compound could revolutionize treatment options for alcohol dependence.

But that's not all. The episode also touches on the latest buzz in the pharmacy world, with Wal-Mart and CVS making headlines for their refusal to fill certain telemedicine prescriptions. This controversial move raises important questions about access to medication and the future of telehealth. Additionally, Drs. Del Tredici and Keenan delve into the role of gabapentin in overdose deaths and its effectiveness for treating neuropathic pain.

They review recent findings from the CDC and Cochrane Database, providing a comprehensive look at this widely prescribed medication. The conversation doesn't stop there. The hosts also bring up the concept of Mendelian randomization, discussing its implications for understanding the relationship between alcohol use disorder and cardiovascular disease. This episode is packed with insights and expert opinions that are sure to leave you thinking long after it ends.

Whether you're a healthcare professional or someone interested in the latest addiction treatment research, this episode offers valuable information and thought-provoking discussions.